Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
UKNSCC London 2016 E-cigarettes for lung cancer patients Lesley Sinclair on behalf of study team Outline • • • • • Background Aims of objectives Methods Challenges to date Progress so far Feasibility & acceptability of electronic cigarettes as an aid to smoking cessation for lung cancer patients Funded by: Roy Castle Lung Cancer Foundation Grant Holders/Project Team Professor Linda Bauld, University of Stirling Dr Stephen Harrow Beatson West of Scotland Cancer Centre Dr Hayden McRobbie, University of Auckland, New Zealand Ms Lesley Sinclair, University of Stirling Dr Kirsten Laws, ANCOR Unit, Aberdeen Royal Infirmary Ms Jennifer McKell, University of Stirling with assistance from Mr Andy Morrison, New Nicotine Alliance Collaborators Professor Anthony Chalmers, University of Glasgow, Professor John Britton, University of Nottingham, Dr Kevin N Franks, St James Institute of Oncology and University of Leeds Background • Tobacco use is leading preventable cause of cancer 64,500 cases in UK each year • 37,200 lung cancer cases • In UK around 30% of lung cancer patients still smoking at time of diagnosis (Park et al 2012) • Recent audit in study site found 2 out of 3 lung cancer patients being treated with curative intent with radiotherapy or combination chemo/radio therapy still smoking during treatment Smoking and cancer treatment • Continued smoking can have adverse outcomes for cancer patients undergoing treatment. The 2014 US Surgeon General’s Report concluded that: In cancer patients and survivors, the evidence is suggestive but not sufficient to infer a causal relationship between cigarette smoking and the risk of recurrence, poor response to treatment, and increased treatment-related toxicity • Other research suggests that patients undergoing radiotherapy who smoke are at increased risk of recurrence, a 2nd cancer developing, or death (Warren et al, 2014) • Smoking cessation relevant for primary and secondary prevention Why might smoking affect cancer treatment? • Number of mechanisms by which continued smoking might undermine different cancer treatments: – Smoking has effect on cancer cell proliferation (contributing to the initiation, promotion and progression of cancer) – Some of the toxicants in tobacco smoke have also been shown to slow down cancer cell death – Tobacco smoke may increase metastasis and may affect tumour cell immune responses Why electronic cigarettes? • E-cigarettes form part of current tobacco harm reduction policy ‘landscape’ in UK (NICE, 2013, RCP, 2016) • Controversial but widely used (2.8 million users) • Hypothesis: may be particularly valuable for groups of smokers who have tried other approaches to stopping smoking and failed – could include lung cancer patients • Results from recently conducted study by members of team on cancer diagnosis as opportunity for smoking cessation in Scotland (Wells et al, 2015) found that: – Although cancer patients who smoked were motivated to quit, many found this difficult – Very few knew about, were referred to, or accessed, stop smoking services – Stop smoking services also not set up in way that made them accessible to cancer patients undergoing treatment • Alternative approaches need testing Aims and Objectives Explore if e-cigs viable alternative to aid smoking cessation for stage IV lung cancer patients • Assess feasibility and acceptability of providing e-cigs with advice & support • Explore views of lung cancer patients, family & friends & professionals • Examine how patients respond to & use e-cigs • Monitor cessation outcomes during treatment period • Assess perceptions of care, support & e-cig use Inform future trial on benefits to survival & QoL Methods Study Design: 12 month pilot study with nested qualitative evaluation of feasibility & acceptability Participants: 25 smokers aged >=18yrs with stage IV lung cancer about to start chemotherapy treatment who agree to try to stop smoking Intervention: Provision of 2nd generation e-cig & liquid with advice & support from experienced vaper whilst undergoing cancer treatment; No control group Key Outcomes: Feasibility & acceptability of stopping/reducing smoking using e-cig; smoking cessation (CO verified)/reduction at 12 weeks; perceptions of e-cig use & support offered Challenges to Date (1) NHS Ethics Thoracic oncologist interested in smoking cessation Oncology Team Collaboration Dr Stephen Harrow and team at CRUK funded Beatson West of Scotland Cancer Centre agreed to collaborate Challenges to Date (2) Choice of e-cig SmokeMax Power 1300 Challenges to Date (3) Will any patients be interested? Supporting patients to use e-cig & overcome barriers Progress to Date • Recruitment started 17th May • About 6 eligible patients approached • 4 patients (3 women, 1 man) recruited & visited at home to get started • Further 1 patient referred to study • Follow-up at 3 days so far Questions? [email protected] Study Flow Diagram